Inc.'s results from ENTRUST study on pegozafermin for Severe Hypertriglyceridemia expected in 2025. Click for this updated ...

Completed enrollment in Phase 3 ENTRUST trial in patients with severe hypertriglyceridemia (SHTG); topline 26-week data expected in the second ...

A thrombopoietin agonist raises platelet counts in HCV-positive patients who are undergoing antiviral therapy. Cirrhotic patients who are infected with hepatitis C virus (HCV) often experience ...

(ETNB) provided a corporate update and business outlook for 2025. Completed enrollment in Phase 3 ENTRUST trial in patients with severe ...

China: A recent study on cirrhotic patients with acute variceal bleeding (AVB) found that thrombocytopenia does not ...

However, data on the incidence and prevalence of CAD in cirrhotic patients are heterogeneous, and the association remains uncertain. In this study, we aimed to conduct a systematic review and meta ...

While Child score was originally designed for assessing the prognosis of cirrhotic patients undergoing surgical treatment of portal hypertension, MELD score was designed for assessing the ...

The FDA has granted premarket approval to Sequana Medical’s alfapump implantable device for the treatment of recurrent or refractory ascites due to cirrhosis, according to a company press release.